Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)

pCPA File Number: 21069

Negotiation Status:

Concluded with an LOI

Indication(s):

Chronic Obstructive Pulmonary Disease (COPD)

Sponsor/Manufacturer:

GlaxoSmithKline Inc.

CDA-AMC Project Number:

SR0562-000

pCPA Engagement Letter Issued:

2018-11-30

Negotiation Process Concluded:

2019-09-09